162 related articles for article (PubMed ID: 12810436)
1. Efficacy of infliximab in psoriatic arthritis resistant to treatment with disease modifying antirheumatic drugs: an open pilot study.
Provenzano G; Termini A; Le Moli C; Rinaldi F
Ann Rheum Dis; 2003 Jul; 62(7):680-1. PubMed ID: 12810436
[No Abstract] [Full Text] [Related]
2. Long term infliximab treatment for severe psoriatic arthritis: evidence of sustained clinical and radiographic response.
Rinaldi F; Provenzano G; Termini A; Spinello M; La Seta F
Ann Rheum Dis; 2005 Sep; 64(9):1375-6. PubMed ID: 16100346
[No Abstract] [Full Text] [Related]
3. Repeated infusions of low-dose infliximab plus methotrexate in psoriatic arthritis: immediate benefits are not maintained after discontinuation of infliximab.
Covelli M; Scioscia C; Iannone F; Lapadula G
Clin Exp Rheumatol; 2005; 23(2):145-51. PubMed ID: 15895882
[TBL] [Abstract][Full Text] [Related]
4. Rapidly progressive destructive arthritis in psoriatic arthritis sine psoriasis: do bone resorption marker levels predict outcome of bone destruction in psoriatic arthritis?
Taniguchi Y; Kumon Y; Shimamura Y; Kobayashi S; Terada Y
Mod Rheumatol; 2011 Feb; 21(1):106-8. PubMed ID: 20625790
[No Abstract] [Full Text] [Related]
5. Prediction of major clinical response (ACR50) to infliximab in psoriatic arthritis refractory to methotrexate.
Gratacós J; Casado E; Real J; Torre-Alonso JC
Ann Rheum Dis; 2007 Apr; 66(4):493-7. PubMed ID: 17179176
[TBL] [Abstract][Full Text] [Related]
6. Healing of psoriatic skin lesions, and improvement of psoriatic arthritis resistant to immunosuppressive drugs, after infliximab treatment.
Nikas SN; Voulgari PV; Takalou IP; Katsimbri P; Drosos AA
Ann Rheum Dis; 2005 Nov; 64(11):1665-7. PubMed ID: 16227426
[No Abstract] [Full Text] [Related]
7. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
Antoni CE; Kavanaugh A; Kirkham B; Tutuncu Z; Burmester GR; Schneider U; Furst DE; Molitor J; Keystone E; Gladman D; Manger B; Wassenberg S; Weier R; Wallace DJ; Weisman MH; Kalden JR; Smolen J
Arthritis Rheum; 2005 Apr; 52(4):1227-36. PubMed ID: 15818699
[TBL] [Abstract][Full Text] [Related]
8. Etanercept plus ciclosporin versus etanercept plus methotrexate for maintaining clinical control over psoriatic arthritis: a randomised pilot study.
Atzeni F; Boccassini L; Antivalle M; Salaffi F; Sarzi-Puttini P
Ann Rheum Dis; 2011 Apr; 70(4):712-4. PubMed ID: 20810394
[No Abstract] [Full Text] [Related]
9. Infliximab treatment in two patients with psoriatic arthritis and secondary IgA nephropathy.
Sakellariou GT; Vounotrypidis P; Berberidis C
Clin Rheumatol; 2007 Jul; 26(7):1132-3. PubMed ID: 16924391
[No Abstract] [Full Text] [Related]
10. Infliximab for psoriasis and psoriatic arthritis.
Antoni C; Manger B
Clin Exp Rheumatol; 2002; 20(6 Suppl 28):S122-5. PubMed ID: 12463461
[TBL] [Abstract][Full Text] [Related]
11. Multidisciplinary focus on methotrexate in psoriatic disesase.
Marchesoni A; Ricci M; Moggio E; Brazzelli V; Borroni G
J Rheumatol Suppl; 2009 Aug; 83():56-8. PubMed ID: 19661543
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of leflunomide and infliximab versus methotrexate and infliximab combination therapy in rheumatoid arthritis.
Cobo Ibáñez T; Yehia Tayel M; Balsa Criado A; Hernández Sanz A; Martín Mola E
Rheumatology (Oxford); 2005 Nov; 44(11):1467-8. PubMed ID: 16174647
[No Abstract] [Full Text] [Related]
13. Long term treatment of psoriatic arthritis with infliximab.
Yazdani-Biuki B; Wohlfahrt K; Mulabecirovic A; Mueller T; Hermann J; Graninger WB; Brezinschek HP; Brezinschek RI
Ann Rheum Dis; 2004 Nov; 63(11):1531-2; author reply 1532. PubMed ID: 15479917
[No Abstract] [Full Text] [Related]
14. Tumour necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors.
Mease PJ
Ann Rheum Dis; 2002 Apr; 61(4):298-304. PubMed ID: 11874829
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of biosimilar infliximab CT-P13 in the treatment of psoriasis and psoriatic arthritis: 1-year follow-up.
Kurizky PS; Galvão LO; Martins GA
An Bras Dermatol; 2019; 94(4):483-484. PubMed ID: 31644629
[No Abstract] [Full Text] [Related]
16. Bone anabolic changes progress in psoriatic arthritis patients despite treatment with methotrexate or tumour necrosis factor inhibitors.
Finzel S; Kraus S; Schmidt S; Hueber A; Rech J; Engelke K; Englbrecht M; Schett G
Ann Rheum Dis; 2013 Jul; 72(7):1176-81. PubMed ID: 22915620
[TBL] [Abstract][Full Text] [Related]
17. Psoriatic arthritis treated by anti-TNFs: a monocentric trial of 102 cases in Auvergne, France.
Soubrier M; Pereira B; Frayssac T; Abdi D; Couderc M; Daron C; Malochet-Guinamand S; Mathieu S; Tatar Z; Tournadre A; Dubost JJ
Clin Exp Rheumatol; 2016; 34(6):1059-1064. PubMed ID: 27607233
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of infliximab for the treatment of psoriatic arthritis.
Ritchlin C
Nat Clin Pract Rheumatol; 2006 Jun; 2(6):300-1. PubMed ID: 16932707
[No Abstract] [Full Text] [Related]
19. Therapies for dactylitis in psoriatic arthritis. A systematic review.
Helliwell PS
J Rheumatol; 2006 Jul; 33(7):1439-41. PubMed ID: 16724369
[TBL] [Abstract][Full Text] [Related]
20. Comparison of different outcome measures for psoriatic arthritis in patients treated with infliximab or placebo.
Vander Cruyssen B; De Keyser F; Kruithof E; Mielants H; Van den Bosch F
Ann Rheum Dis; 2007 Jan; 66(1):138-40. PubMed ID: 17178763
[No Abstract] [Full Text] [Related]
[Next] [New Search]
